Research Compound Overview

PT-141 (Bremelanotide): Melanocortin Receptor Research — MC4R Signaling, CNS Pharmacology & Structure-Activity

Last updated: July 2, 2026 · peer-reviewed receptor pharmacology literature referenced

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide derived from the α-melanocyte-stimulating hormone (α-MSH) family and developed from the earlier melanocortin analog melanotan II. In the published literature it is studied as an agonist of the melanocortin receptor family — a set of five G-protein-coupled receptors (MC1R–MC5R) that regulate diverse physiological signaling. PT-141 is of particular interest to receptor pharmacology researchers because it displays a distinctive affinity profile, binding with highest potency to the MC4R and MC3R subtypes that are densely expressed in the central nervous system.

What makes PT-141 notable as a research tool is its conformationally constrained structure. Where the endogenous α-MSH hormone is a linear, rapidly degraded peptide, PT-141 incorporates a lactam bridge that locks the pharmacophore into a rigid ring. This constraint has made it a recurring reference compound in structure-activity and receptor-selectivity studies of the melanocortin system.

Chemical Profile

Primary Mechanisms of Action

1. MC4R Agonism and cAMP Signaling

The most extensively studied action of PT-141 in the literature is its agonism at the melanocortin-4 receptor (MC4R). MC4R is a Gs-coupled G-protein-coupled receptor: when an agonist occupies its binding pocket, the receptor activates adenylyl cyclase, which raises intracellular cyclic adenosine monophosphate (cAMP). This cAMP signal is the canonical readout used in cell-based melanocortin assays to quantify agonist potency and efficacy.

MC4R itself is one of the most thoroughly characterized receptors in metabolic and neuroendocrine research. A comprehensive review in Endocrine Reviews details its physiology, pharmacology, and the pathophysiology associated with its loss-of-function mutations, establishing the receptor-level framework against which agonists such as PT-141 are studied.

2. Central Melanocortin System Signaling

PT-141's affinity profile directs research attention to the central melanocortin system — the population of MC3R and MC4R found in hypothalamic and limbic circuits. In this literature, melanocortin tone is examined as a regulator of energy balance and neuroendocrine output. Because PT-141 acts as an agonist at these central receptors, it is used experimentally to interrogate how melanocortin signaling propagates through the brain, distinct from peripheral melanocortin actions on pigment cells or the adrenal cortex.

A review in Nature Reviews Endocrinology surveys efforts to target the central melanocortin system, situating melanocortin agonists within a broader program of receptor pharmacology aimed at understanding how MC3R/MC4R circuits govern physiology.

3. Cyclic Peptide Structure-Activity

The lactam bridge that defines PT-141 is a structure-activity feature, not merely a stability enhancement. By constraining the peptide backbone into a ring, the bridge pre-organizes the His-Phe-Arg-Trp core sequence — the segment identified across melanocortin research as essential for receptor recognition — into a bioactive conformation. Structural biology studies of cyclic and linear melanocortin analogues examine how ring size and conformational rigidity translate into receptor affinity and functional potency.

4. Receptor Structure and Ligand Recognition

Advances in cryo-electron microscopy have resolved how melanocortin peptide agonists engage the MC4R binding pocket at near-atomic resolution. These structures capture the agonist-bound, active-state receptor coupled to its Gs protein and reveal the conformational rearrangements — including movements of transmembrane helix 6 and a ligand-bridging calcium ion — that accompany receptor activation. Such work provides the molecular template for interpreting the pharmacology of cyclic melanocortin agonists like PT-141.

Research Applications

Melanocortin Receptor Pharmacology

PT-141 serves as a reference agonist in melanocortin receptor pharmacology. Because its affinity is weighted toward MC4R and MC3R, it is used in comparative binding and functional assays to benchmark subtype selectivity and to calibrate the cAMP response of engineered cell lines expressing individual melanocortin receptor subtypes.

Central Nervous System Signaling Research

The centrally expressed MC3R and MC4R make PT-141 a tool for probing melanocortin signaling in neuroendocrine models. Researchers use it to examine how agonist occupancy of these receptors modulates downstream cAMP-dependent pathways within neural tissue models, contributing to the broader map of how the melanocortin system integrates central and peripheral signals.

Cell-Model and Oncology-Adjacent Research

Melanocortin receptors are expressed on a range of cell types beyond neurons, and PT-141 has appeared in cell-model studies exploring receptor-mediated effects on proliferation and survival. A study in Anticancer Research examined bremelanotide as a melanocortin receptor agonist in glioblastoma cell lines, reporting effects on cell growth and survivin expression — an example of how a melanocortin agonist is deployed as a probe in in vitro cancer-cell biology.

Cardiovascular Pharmacology Characterization

Melanocortin receptors are also involved in cardiovascular regulation, and the pharmacology literature includes systematic characterization of a melanocortin agonist's hemodynamic profile. A study in the Journal of Hypertension applied ambulatory blood-pressure monitoring to assess bremelanotide, illustrating the kind of quantitative pharmacological characterization performed on melanocortin receptor agonists.

Comparison with Other Melanocortin Research Compounds

Within melanocortin research, compounds are distinguished largely by their receptor-subtype selectivity. PT-141 is derived from melanotan II, a broad-spectrum α-MSH analog that activates all five melanocortin subtypes; the structural refinements that produced PT-141 shifted the balance toward the centrally expressed MC4R and MC3R. This makes the PT-141 / melanotan II pair a useful comparison in the literature for studying how modest structural changes redistribute activity across a homologous receptor family.

Against fully MC1R-selective or MC5R-selective research ligands, PT-141's central-receptor weighting places it in a different functional niche. This partitioning is what allows researchers to attribute observed signaling to specific receptor subtypes rather than to melanocortin activation in general.

Research Limitations

Although PT-141 is a well-characterized melanocortin agonist, its cross-reactivity across the melanocortin family is a genuine interpretive limitation. Peptidic melanocortin agonists generally retain measurable affinity at multiple subtypes, so effects observed in a mixed-receptor system cannot always be attributed to a single receptor without selective antagonist controls or receptor-knockout models.

Additionally, much of the detailed structural and functional work on melanocortin receptors has been performed on MC4R and MC1R, while MC3R pharmacology remains comparatively less resolved. Because PT-141 engages both MC3R and MC4R, disentangling the relative contribution of each subtype in a given research model continues to require careful experimental design.